2021 ASCO Annual Meeting Bookmark

Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

.

ARIEL4 Trial Confirms PFS Benefit of Rucaparib in BRCA+ Relapsed Ovarian Cancer Bookmark

As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.

.

FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy Bookmark

On May 28, 2021, the U.S. Food and Drug Administration granted Accelerated Approval for Lumakras (sotorasib), the first targeted therapy for cancer with a mutation in the KRAS gene.

.

Advances in Colorectal Cancer Research Bookmark

This outline from the National Cancer Institute covers recent research on colorectal cancer.

.

Cancer Support for LGBTQIA Patients Is Missing Bookmark

This piece from ASCO Connection outlines the need for and a path to improvement in cancer care for LGBTQIA patients.

.

Hepatocellular Carcinoma (HCC)—An Overview Bookmark

Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

This 2020 encyclopedic approach to all of the many diagnostic and therapeutic options available for primary hepatocellular carcinoma leaves no stone unturned. (Free registration required, written with a physician audience in mind.)

.

Sydney Researchers Identify/Advance Potential Revolutionary New Drug Treatment for Fatal Childhood Cancer Bookmark

A press release from the Children’s Cancer Institute outlines hopeful results from experiments performed in mice and 3-D computer models that investigated a new treatment for the rare childhood brain tumor diffuse intrinsic pontine glioma (DIPG). The treatment consists of a combination of the drugs difluoromethylornithine (DFMO) and AMXT 1501. This combo is already being tested in clinical trials in adults with cancer, and will soon be tested in children with DIPG.

.

Chemo for Glioblastoma May Work Better in Morning Than Evening Bookmark

A press release from ScienceDaily outlines results from a small study of patients receiving a standard, FDA-approved treatment (temozolomide) for glioblastoma. The results suggest that some patients may survive a few months longer, all because of time of day for administering the drug.

.

FDA Approves New Treatment For Adults With Relapsed Or Refractory Large-B-Cell Lymphoma Bookmark

The U.S. Food and Drug Administration (FDA) has approved a cell-based gene therapy known as lisocabtagene maraleucel (brand name Breyanzi) for relapsed or refractory large B-cell lymphoma.

.

Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark

The ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.

.